Arecor Therapeutics plc is a clinical-stage biotech company developing therapeutics aimed at reducing treatment burden and improving outcomes for individuals with diabetes, obesity, and other cardiometabolic diseases. Its lead product, AT278, is an ultra-concentrated ultra-rapid-acting insulin in development, designed to enhance automated insulin delivery systems. Arecor is also working on a novel oral delivery platform for peptides, targeting GLP-1 receptor agonists as its first validation. The company is based in Cambridge, UK.